Circulation. 2002;106:2184-2187
Published online before print October 7, 2002, doi: 10.1161/01.CIR.0000037521.71373.44
Published online before print October 7, 2002, doi: 10.1161/01.CIR.0000037521.71373.44
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:2184.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Anti–Tumor Necrosis Factor-
Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis
From Cardiology (D.H., G.N., F.E., R.C., M.B., L.E.S., T.F.L.) and Department of Rheumatology and Institute for Physical Medicine (A.F., O.D., M.N., B.A.M., R.E.G., S.G.), University Hospital, Zürich, Switzerland.
Correspondence to Frank Ruschitzka, MD, FESC, Cardiology, University Hospital, Rämistrasse 100, CH-8091 Zürich, Switzerland. E-mail frankruschitzka{at}yahoo.com
Background— Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis and increased cardiovascular morbidity and mortality. Striking similarities exist in the inflammatory and immunologic response in RA and atherosclerosis. Indeed, adhesion molecules and cytokines, tumor necrosis factor (TNF)-
in particular, are key mediators of joint inflammation and of vascular dysfunction and progression of atherosclerotic vascular disease. Hence, the aim of the present study was to assess the effect of chronic antiinflammatory treatment with the anti-TNF- antibody infliximab on disease activity and endothelial function in patients with active RA.
Methods and Results— Eleven RA patients (mean age 46±5 years; disease duration 9±2 years) with high disease activity despite treatment with stable doses of methotrexate (
25 mg/wk) and prednisone (10 mg/d) were investigated. Clinical status and endothelium-dependent and -independent vasodilation of the brachial artery as assessed by high-resolution ultrasound were measured before and after 12 weeks of infliximab therapy. Flow-mediated vasodilation improved from 3.2±0.4% to 4.1±0.5% (P=0.018), whereas endothelium-independent vasodilation with nitroglycerin and baseline diameter remained unchanged (13.6±1.2% versus 12.8±1.4%, P=0.98, and 3.74±0.15 versus 3.66±0.11 mm, P=0.54, respectively). Disease activity score (DAS28) was significantly reduced, from 5.6±0.3 to 3.5±0.6 (P=0.002). Erythrocyte sedimentation rate and C-reactive protein were lowered from 34±7 to 19±5 mm/h (P=0.04) and from 38±11 to 15±10 mg/L (P=0.08), respectively.
Conclusions— This is the first study to show that anti-TNF- treatment improves endothelial function in RA. The data suggest that in RA, endothelial dysfunction is part of the disease process and is mediated by TNF-.
Key Words: endothelium • inflammation • atherosclerosis • risk factors
This article has been cited by other articles:
 |
|
 |
|
  B. Galarraga, F. Khan, P. Kumar, T. Pullar, and J. J. F. Belch Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis Rheumatology, November 1, 2009; 48(11): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Hamdulay and J. C Mason Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA? Heart, September 15, 2009; 95(18): 1471 - 1472. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Recio-Mayoral, J. C. Mason, J. C. Kaski, M. B. Rubens, O. A. Harari, and P. G. Camici Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease Eur. Heart J., August 1, 2009; 30(15): 1837 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C A Wijbrandts, S I van Leuven, H D Boom, D M Gerlag, E G S Stroes, J J P Kastelein, and P P Tak Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis Ann Rheum Dis, August 1, 2009; 68(8): 1316 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Turiel, F. Atzeni, L. Tomasoni, S. de Portu, L. Delfino, B. D. Bodini, M. Longhi, S. Sitia, M. Bianchi, P. Ferrario, et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients Rheumatology, July 1, 2009; 48(7): 834 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I C van Eijk, M J L Peters, E H Serne, I E van der Horst-Bruinsma, B A C Dijkmans, Y M Smulders, and M T Nurmohamed Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor {alpha} blockade Ann Rheum Dis, March 1, 2009; 68(3): 362 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Montecucco and F. Mach Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis Rheumatology, January 1, 2009; 48(1): 11 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Dumitriu, E. T. Araguas, C. Baboonian, and J. C. Kaski CD4+CD28null T cells in coronary artery disease: when helpers become killers Cardiovasc Res, January 1, 2009; 81(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Galarraga, F. Khan, P. Kumar, T. Pullar, and J. J. F. Belch C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis Rheumatology, December 1, 2008; 47(12): 1780 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Flammer, I. Sudano, F. Hermann, F. Enseleit, D. Periat, M. Hermann, T. F. Luscher, R. Corti, G. Noll, F. Ruschitzka, et al. Response to Letter Regarding Article, "Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis" Circulation, November 4, 2008; 118(19): e691 - e691. [Full Text] [PDF]
|
|
|
|
|
|
I. Ikonomidis, J. P. Lekakis, M. Nikolaou, I. Paraskevaidis, I. Andreadou, T. Kaplanoglou, P. Katsimbri, G. Skarantavos, P. N. Soucacos, and D. T. Kremastinos Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis Circulation, May 20, 2008; 117(20): 2662 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Flammer, I. Sudano, F. Hermann, S. Gay, A. Forster, M. Neidhart, P. Kunzler, F. Enseleit, D. Periat, M. Hermann, et al. Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis Circulation, April 29, 2008; 117(17): 2262 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. van Leuven, R. Franssen, J. J. Kastelein, M. Levi, E. S. G. Stroes, and P. P. Tak Systemic inflammation as a risk factor for atherothrombosis Rheumatology, January 1, 2008; 47(1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Popa, F. H J van den Hoogen, T. R D J Radstake, M. G Netea, A. E Eijsbouts, M. d. Heijer, J. W M van der Meer, P. L C M van Riel, A. F H Stalenhoef, and P. Barrera Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis Ann Rheum Dis, November 1, 2007; 66(11): 1503 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Grisar, D. Aletaha, C. W Steiner, T. Kapral, S. Steiner, M. Saemann, I. Schwarzinger, B. Buranyi, G. Steiner, and J. S Smolen Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy Ann Rheum Dis, October 1, 2007; 66(10): 1284 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W G Dixon and D P M Symmons What effects might anti-TNF{alpha} treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF{alpha} in cardiovascular pathophysiology Ann Rheum Dis, September 1, 2007; 66(9): 1132 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Maki-Petaja, A. D. Booth, F. C. Hall, S. M.L. Wallace, J. Brown, C. M. McEniery, and I. B. Wilkinson Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis J. Am. Coll. Cardiol., August 28, 2007; 50(9): 852 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Carmona, M. A. Descalzo, E. Perez-Pampin, D. Ruiz-Montesinos, A. Erra, T. Cobo, J. J Gomez-Reino, and on behalf of the BIOBADASER and EMECAR Groups All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists Ann Rheum Dis, July 1, 2007; 66(7): 880 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Del Porto, B. Lagana, S. Lai, I. Nofroni, F. Tinti, M. Vitale, E. Podesta, A. P. Mitterhofer, and R. D'Amelio Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis Rheumatology, July 1, 2007; 46(7): 1111 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Haubitz Exploring new territory: the move towards individualised treatment Lupus, March 1, 2007; 16(3): 227 - 231. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Csiszar, N. Labinskyy, K. Smith, A. Rivera, Z. Orosz, and Z. Ungvari Vasculoprotective Effects of Anti-Tumor Necrosis Factor-{alpha} Treatment in Aging Am. J. Pathol., January 1, 2007; 170(1): 388 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Quyyumi Inflamed Joints and Stiff Arteries: Is Rheumatoid Arthritis a Cardiovascular Risk Factor? Circulation, September 12, 2006; 114(11): 1137 - 1139. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Maki-Petaja, F. C. Hall, A. D. Booth, S. M.L. Wallace, Yasmin, P. W.P. Bearcroft, S. Harish, A. Furlong, C. M. McEniery, J. Brown, et al. Rheumatoid Arthritis Is Associated With Increased Aortic Pulse-Wave Velocity, Which Is Reduced by Anti-Tumor Necrosis Factor-{alpha} Therapy Circulation, September 12, 2006; 114(11): 1185 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rizzello, G. Liuzzo, S. Brugaletta, A. Rebuzzi, L. M. Biasucci, and F. Crea Modulation of CD4+CD28null T Lymphocytes by Tumor Necrosis Factor-{alpha} Blockade in Patients With Unstable Angina Circulation, May 16, 2006; 113(19): 2272 - 2277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Bernstein, J. Berry, S. Kim, B. Canavan, and S. K. Grinspoon Effects of Etanercept in Patients With the Metabolic Syndrome. Arch Intern Med, April 24, 2006; 166(8): 902 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hermann and F. Ruschitzka Novel anti-inflammatory drugs in hypertension Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864. [Full Text] [PDF]
|
|
|
|
|
|
S I van Leuven, J J. Kastelein, D P D'Cruz, G R Hughes, and E S Stroes Atherogenesis in rheumatology Lupus, March 1, 2006; 15(3): 117 - 121. [Abstract] [PDF]
|
|
|
|
|
|
F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Van Doornum, G. McColl, and I. P. Wicks Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis Rheumatology, November 1, 2005; 44(11): 1428 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grundmann, I. Hoefer, S. Ulusans, N. van Royen, S. H. Schirmer, C. K. Ozaki, C. Bode, J. J. Piek, and I. Buschmann Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1497 - H1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Gerli and N J Goodson Cardiovascular involvement in rheumatoid arthritis Lupus, September 1, 2005; 14(9): 679 - 682. [Abstract] [PDF]
|
|
|
|
|
|
P Sarzi-Puttini, F Atzeni, A Doria, L Iaccarino, and M Turiel Tumor necrosis factor-a, biologic agents and cardiovascular risk Lupus, September 1, 2005; 14(9): 780 - 784. [Abstract] [PDF]
|
|
|
|
|
|
C. D. Buckley, G. E. Rainger, G. B. Nash, and K. Raza Endothelial cells, fibroblasts and vasculitis Rheumatology, July 1, 2005; 44(7): 860 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Roman, R. B. Devereux, J. E. Schwartz, M. D. Lockshin, S. A. Paget, A. Davis, M. K. Crow, L. Sammaritano, D. M. Levine, B.-A. Shankar, et al. Arterial Stiffness in Chronic Inflammatory Diseases Hypertension, July 1, 2005; 46(1): 194 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Taylor Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy Rheumatology, June 1, 2005; 44(6): 721 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hermann, A. Forster, R. Chenevard, F. Enseleit, D. Hurlimann, R. Corti, L. E. Spieker, D. Frey, M. Hermann, W. Riesen, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis J. Am. Coll. Cardiol., February 1, 2005; 45(3): 461 - 464. [Full Text] [PDF]
|
|
|
|
|
|
C Popa, M G Netea, T Radstake, J W M Van der Meer, A F H Stalenhoef, P L C M van Riel, and P Barerra Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis Ann Rheum Dis, February 1, 2005; 64(2): 303 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Grisar, D. Aletaha, C. W. Steiner, T. Kapral, S. Steiner, D. Seidinger, G. Weigel, I. Schwarzinger, W. Wolozcszuk, G. Steiner, et al. Depletion of Endothelial Progenitor Cells in the Peripheral Blood of Patients With Rheumatoid Arthritis Circulation, January 18, 2005; 111(2): 204 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I B McInnes, D W McCarey, and N Sattar Do statins offer therapeutic potential in inflammatory arthritis? Ann Rheum Dis, December 1, 2004; 63(12): 1535 - 1537. [Full Text] [PDF]
|
|
|
|
|
|
S Van Doornum, G McColl, and I P Wicks Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis Ann Rheum Dis, December 1, 2004; 63(12): 1571 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gonzalez-Juanatey, M. A. Gonzalez-Gay, N. Sattar, D. W. McCarey, H. Capell, and I. B. McInnes Rheumatoid Arthritis and Accelerated Atherogenesis * Response Circulation, June 29, 2004; 109(25): e328 - e328. [Full Text] [PDF]
|
|
|
|
|
|
R. Gerli, G. Schillaci, A. Giordano, E. B. Bocci, O. Bistoni, G. Vaudo, S. Marchesi, M. Pirro, F. Ragni, Y. Shoenfeld, et al. CD4+CD28- T Lymphocytes Contribute to Early Atherosclerotic Damage in Rheumatoid Arthritis Patients Circulation, June 8, 2004; 109(22): 2744 - 2748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G F Ferraccioli and E Gremese Autoantibodies and thrombophilia in RA: TNF{alpha} and TNF{alpha} blockers Ann Rheum Dis, June 1, 2004; 63(6): 613 - 615. [Full Text]
|
|
|
|
|
|
A.D. Booth, D.R.W. Jayne, R.K. Kharbanda, C.M. McEniery, I.S. Mackenzie, J. Brown, and I.B. Wilkinson Infliximab Improves Endothelial Dysfunction in Systemic Vasculitis: A Model of Vascular Inflammation Circulation, April 13, 2004; 109(14): 1718 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Arenas, Y. Xu, P. Lopez-Jaramillo, and S. T. Davidge Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-{alpha} Am J Physiol Cell Physiol, April 1, 2004; 286(4): C779 - C784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Vaudo, S Marchesi, R Gerli, R Allegrucci, A Giordano, D Siepi, M Pirro, Y Shoenfeld, G Schillaci, and E Mannarino Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity Ann Rheum Dis, January 1, 2004; 63(1): 31 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar, D. W. McCarey, H. Capell, and I. B. McInnes Explaining How "High-Grade" Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis Circulation, December 16, 2003; 108(24): 2957 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. He, C. Rask-Madsen, and G.L. King Mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B51 - B57. [Abstract] [PDF]
|
|